Bone Diseases Clinical Trials

A listing of Bone Diseases medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently, reduced intensity conditioning (RIC) regimens have been used for both adult patients

alemtuzumab
shortening fraction
severe combined immunodeficiency
reduced intensity conditioning
melphalan
  • 1 views
  • 14 Mar, 2021
  • 1 location
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

This Phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant. Patients receiving a donor stem cell transplant may experience accelerated bone loss and an increase risk of bone fractures, …

osteoporosis
RANKL
denosumab
osteopenia
x-ray absorptiometry
  • 53 views
  • 22 Oct, 2021
  • 2 locations
Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma

This is a randomized unblinded Phase II clinical trial evaluating the impact of intensive antihypertensive control (targeted to the 50-75th percentile for age, sex, and height) compared to conventional antihypertensive control (targeted to the 90-95th percentile for age, sex, and height) on the incidence of radiographically extensive osteonecrosis in children …

hypertension
lymphoblastic leukemia
lisinopril
leukemia
antihypertensive drugs
  • 0 views
  • 19 Jan, 2022
  • 3 locations
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.

monoclonal antibodies
serum calcium
monoclonal protein
plasmacytoma
vasectomy
  • 0 views
  • 27 Jan, 2021
  • 7 locations
Study of Infigratinib in Children With Achondroplasia

This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) …

tyrosine kinase inhibitor
  • 41 views
  • 26 Dec, 2021
  • 17 locations
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery

  • 8 views
  • 05 Aug, 2021
  • 3 locations
A Study Of Safety Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Approximately 63 participants will be randomized to one of three doses to receive Recifercept either Low Dose Medium Dose High Dose Participants will will attend the clinic at baseline and at Day 1, 4, 8, 15, 29 & then Month 2, 3 6, 9 & 12. Assessments include safety, blood …

testicular
  • 11 views
  • 22 Oct, 2021
  • 11 locations
Extension Study of Infigratinib in Children With Achondroplasia (ACH)

This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in subjects with ACH who previously completed a QED-sponsored interventional study, and potentially in additional subjects who are naïve to infigratinib treatment. Treatment-naïve subjects …

  • 0 views
  • 12 Dec, 2021
  • 1 location
Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. The administration period of teriparatide is from 6 to 12 months and thereafter, …

teriparatide
osteoporosis
bone mineral density
forteo
denosumab
  • 130 views
  • 29 Sep, 2021
  • 1 location
The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

This is a Phase 2 Multi-Center Clinical Trial (safety and effectiveness trial) in 60 patients (40 denosumab; 20 placebo) who have had a kidney transplant for 12-months or longer with more than 30% of kidney function. The investigators will test whether denosumab safely improves bone mineral density (BMD) by dual-energy …

kidney disease
oral surgery
osteopathy
tooth extraction
metabolic bone disease
  • 3 views
  • 22 Jul, 2021
  • 2 locations